Scholarlink

<p>A prevalent complication of chronic kidney disease (CKD), iron deficiency anemia (IDA) continues to be underdiagnosed and undertreated. Anemia in CKD in children is associated with a reduced quality of life, and an increased morbidity and mortality. The multifaceted etiology of anemia in CKD involves factors such as diminished endogenous erythropoietin (EPO) production, absolute or functional iron deficiency, and heightened inflammation characterized by elevated hepcidin levels. This paper reviews the complexities of anemia management in pediatric CKD, emphasizing the pivotal role of iron supplementation and erythropoiesis-stimulating agents (ESAs) in ameliorating erythropoiesis and optimizing patient outcomes. While intravenous (IV) iron supplementation effectively addresses iron-restricted erythropoiesis and enhances ESA response, challenges persist in accurately defining anemia in pediatric CKD patients and establishing appropriate treatment targets.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anemia Management in Pediatric Chronic Kidney Disease: Current Challenges and Treatment Strategies

  • 期刊论文

  • 发表日期：

    2025年1月8日

查看全文
  • Altaf Jamil,
  • Barbara Gruner,
  • Javairia Jamil,
  • Alicia Bach,
  • Tyler Severance,
  • Kim Ebersol,
  • Laura E. Hesemann

摘要

A prevalent complication of chronic kidney disease (CKD), iron deficiency anemia (IDA) continues to be underdiagnosed and undertreated. Anemia in CKD in children is associated with a reduced quality of life, and an increased morbidity and mortality. The multifaceted etiology of anemia in CKD involves factors such as diminished endogenous erythropoietin (EPO) production, absolute or functional iron deficiency, and heightened inflammation characterized by elevated hepcidin levels. This paper reviews the complexities of anemia management in pediatric CKD, emphasizing the pivotal role of iron supplementation and erythropoiesis-stimulating agents (ESAs) in ameliorating erythropoiesis and optimizing patient outcomes. While intravenous (IV) iron supplementation effectively addresses iron-restricted erythropoiesis and enhances ESA response, challenges persist in accurately defining anemia in pediatric CKD patients and establishing appropriate treatment targets.